The Effects of a Government Investigation on Marketing Practices in the Pharmaceutical Industry
Author: M. Dale Beckman
Publisher:
Published: 1968
Total Pages: 640
ISBN-13:
DOWNLOAD EBOOKRead and Download eBook Full
Author: M. Dale Beckman
Publisher:
Published: 1968
Total Pages: 640
ISBN-13:
DOWNLOAD EBOOKAuthor: Marvin Dale Beckman
Publisher:
Published: 1968
Total Pages: 598
ISBN-13:
DOWNLOAD EBOOKAuthor: Institute of Medicine
Publisher: National Academies Press
Published: 1991-02-01
Total Pages: 225
ISBN-13: 030904491X
DOWNLOAD EBOOKAmericans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
Published: 2018-03-01
Total Pages: 235
ISBN-13: 0309468086
DOWNLOAD EBOOKThanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author: Ray Moynihan
Publisher: Greystone Books
Published: 2008-09-01
Total Pages: 171
ISBN-13: 1926706684
DOWNLOAD EBOOKIn this hard-hitting indictment of the pharmaceutical industry, Ray Moynihan and Allan Cassels show how drug companies are systematically using their dominating influence in the world of medical science, drug companies are working to widen the very boundaries that define illness. Mild problems are redefined as serious illness, and common complaints are labeled as medical conditions requiring drug treatments. Runny noses are now allergic rhinitis, PMS has become a psychiatric disorder, and hyperactive children have ADD. Selling Sickness reveals how expanding the boundaries of illness and lowering the threshold for treatments is creating millions of new patients and billions in new profits, in turn threatening to bankrupt national healthcare systems all over the world. This Canadian edition includes an introduction placing the issue in a Canadian context and describing why Canadians should be concerned about the problem.
Author: Dwight D. Eisenhower Library
Publisher:
Published: 1981
Total Pages: 182
ISBN-13:
DOWNLOAD EBOOKAuthor: Great Britain: Parliament: House of Commons: Health Committee
Publisher: The Stationery Office
Published: 2005-04-26
Total Pages: 556
ISBN-13: 9780215024572
DOWNLOAD EBOOKIncorporating HC 1030-i to iii.
Author: Xerox University Microfilms
Publisher:
Published: 1973
Total Pages: 832
ISBN-13:
DOWNLOAD EBOOKAuthor:
Publisher:
Published: 1973
Total Pages: 838
ISBN-13:
DOWNLOAD EBOOKAuthor: Congressional Budget Office
Publisher: Lulu.com
Published: 2013-06-09
Total Pages: 65
ISBN-13: 1304121445
DOWNLOAD EBOOKPerceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...